Page last updated: 2024-10-16

beta-alanine and Dyspepsia

beta-alanine has been researched along with Dyspepsia in 2 studies

Dyspepsia: Impaired digestion, especially after eating.

Research Excerpts

ExcerptRelevanceReference
"Among patients given dabigatran for atrial fibrillation, NB-UGI AEs are generally mild or moderate; 4% stopped taking the drug over a median of 21."5.17Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. ( Aisenberg, J; Bytzer, P; Connolly, SJ; Ezekowitz, M; Formella, S; Reilly, PA; Yang, S, 2013)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schulman, S1
Shortt, B1
Robinson, M1
Eikelboom, JW1
Bytzer, P1
Connolly, SJ1
Yang, S1
Ezekowitz, M1
Formella, S1
Reilly, PA1
Aisenberg, J1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)[NCT03515083]100 participants (Actual)Interventional2017-07-17Completed
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atria[NCT00262600]Phase 318,113 participants (Actual)Interventional2005-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Abnormal Liver Function Test

Number of subjects with abnormal liver function test (LFT), i.e., ALT/AST>3xULN and total bilirubin > 2 x ULN (NCT00262600)
Timeframe: 36 months

Interventionparticipants (Number)
Dabigatran 110 mg11
Dabigatran 150 mg14
Warfarin21

Yearly Event Rate for Composite Endpoint of Stroke/SEE

Time to first occurrence of stroke or systemic embolic event. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg1.54
Dabigatran 150 mg1.11
Warfarin1.71

Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death

Time to first occurrence of stroke, SEE or all cause death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.85
Dabigatran 150 mg4.32
Warfarin5.20

Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death

Time to first occurrence of stroke, systemic embolic event, pulmonary embolism, myocardial infarction including silent myocardial infarction or vascular death. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25 (NCT00262600)
Timeframe: 36 months

Interventionyearly event rate (percentage) (Number)
Dabigatran 110 mg4.26
Dabigatran 150 mg3.68
Warfarin4.35

Bleeding Events (Major and Minor)

"Yearly event rate of bleeds. Yearly event rate (%) = number of subjects with event / subject-years * 100. Subject years = sum(date of study termination - date of randomization + 1) of all randomized subjects / 365.25~Major bleeds are adjudicated, whereas minor bleeds are investigator reported." (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage) (Number)
Major bleedsMinor bleeds
Dabigatran 110 mg2.9913.16
Dabigatran 150 mg3.5514.85
Warfarin3.8116.37

Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH)

Patients with clinical relevant abnormalities for intracerebral hemorrhage, other intracranial hemorrhage (ICH) (NCT00262600)
Timeframe: 36 months

,,
Interventionyearly event rate (percentage)] (Number)
intracerebral hemorrhageintracranial hemorrhage (ICH)
Dabigatran 110 mg0.120.23
Dabigatran 150 mg0.100.32
Warfarin0.380.76

Trials

1 trial available for beta-alanine and Dyspepsia

ArticleYear
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Da

2013

Other Studies

1 other study available for beta-alanine and Dyspepsia

ArticleYear
Adherence to anticoagulant treatment with dabigatran in a real-world setting.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:7

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; b

2013